Sameer J. Patel

Sameer J. Patel

Auto-generated profile, based on publicly available information

Sameer J. Patel

Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, USA; Department of Pediatrics, Northwestern University Feinberg School of Medicine, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
SPSameer J. Patel
Sameer J. Patel
MWMatthew Wellington
Matthew Wellington
RSRohan M. Shah
Rohan M. Shah
MFMatthew J. Ferreira
Matthew J. Ferreira

1 June 2014 in American Journal of Infection Control
Verified
Journal Article
Closed access
SPSameer J. Patel
Sameer J. Patel
AOAndré P. Oliveira
André P. Oliveira
JZJuyan Julia Zhou
Juyan Julia Zhou
LALuis Alba
Luis Alba
EFE. Yoko Furuya
E. Yoko Furuya
LSLisa Saiman
Lisa Saiman

1 August 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
LKLarry K. Kociolek
Larry K. Kociolek
DGDale N. Gerding
Dale N. Gerding
JOJames R. Osmolski
James R. Osmolski
SPSameer J. Patel
Sameer J. Patel
DSDavid R. Snydman
David R. Snydman
DHDavid W. Hecht
David W. Hecht
The rising incidence of Clostridium difficile infections (CDIs) in adults is partly related to the global spread of fluoroquinolone-resistant strains, namely, BI/NAP1/027. Although CDIs are also increasingly diagnosed in children, BI/NAP1/027 is relatively uncommon in children. Little is known about the antibiotic susceptibility of pediatric CDI isolates. C. difficile was cultured from tcdB -positive stools collected from children diagnosed with CDI between December 2012 and December 2013 at an academic children's hospital. CDI isolates were grouped by restriction endonuclease analysis (REA). MICs were measured by agar dilution method for 7 antibiotics. Susceptibility breakpoints were based on guidelines from CLSI and/or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). MICs and REA groupings of C. difficile isolates from 74 adult patients (29 isolates underwent REA) from a temporally and geographically similar adult cohort were compared to those of pediatric isolates. Among 122 pediatric and 74 adult isolates, respectively, the rates of resistance were as follows: metronidazole, 0% and 0%; vancomycin, 0% and 8% ( P = 0.003); rifaximin, 1.6% and 6.7% ( P = 0.11); clindamycin, 18.9% and 25.3% ( P = 0.29); and moxifloxacin, 2.5% and 36% ( P = <0.0001). Only 1 of 122 (0.8%) BI/NAP1/027 isolates was identified among the children, compared to 9 of 29 (31%) isolates identified among the adults ( P = <0.0001). The 3 moxifloxacin-resistant pediatric isolates were of REA groups BI and CF and a nonspecific group. The 2 rifaximin-resistant pediatric isolates were of REA groups DH and Y. The 21 clindamycin-resistant pediatric isolates were distributed among 9 REA groups (groups A, CF, DH, G, L, M, and Y and 2 unique nonspecific REA groups). These data suggest that a diverse array of relatively antibiotic-susceptible C. difficile strains predominate in a cohort of children with CDI compared to adults.

1 October 2021 in Clinical Therapeutics
Verified
Journal Article
Closed access
SPSimon Parzen-Johnson
Simon Parzen-Johnson
KKKenny D. Kronforst
Kenny D. Kronforst
RSRohan M. Shah
Rohan M. Shah
GWGrant Whitmer
Grant Whitmer
TSTonya Scardina
Tonya Scardina
SPSameer J. Patel
Sameer J. Patel

30 May 2022 in Vaccine
Verified
Journal Article
Closed access
EMEmily Merrick
Emily Merrick
JWJoshua P. Weissman
Joshua P. Weissman
SPSameer J. Patel
Sameer J. Patel

14 June 2016 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
SPSameer J. Patel
Sameer J. Patel
NGNicole Green
Nicole Green
SCSarah A. Clock
Sarah A. Clock
DPDavid A. Paul
David A. Paul
JPJeffrey M. Perlman
Jeffrey M. Perlman
LSLisa Saiman
Lisa Saiman
Gram-negative bacilli (GNB) account for a significant burden of infection and colonization in neonatal intensive care units (NICUs), and antibiotic resistance among these pathogens is of increasing concern. A prospective cohort study was performed in 4 NICUs between May 2009 and April 2012. The body sites from which GNB were isolated, antimicrobial susceptibilities of the GNB isolated, and antimicrobial therapy were assessed. Attending neonatologists treated 3.0% (188 of 6184) of eligible infants for GNB infection; 23% of 214 GNB isolates were nonsusceptible to antimicrobial agents, including gentamicin (14.8%), piperacillin-tazobactam (9.9%), third-generation cephalosporin (7.0%), and/or carbapenem agents (4.5%). Gentamicin was the most commonly used antibiotic overall, and much of its use was empiric. However, third-generation cephalosporin agents and cefepime were used more commonly as targeted therapy for identified Gram-negative pathogens. One-quarter of the GNB isolates were nonsusceptible to ≥1 antibiotic. Antimicrobial stewardship strategies for reducing antimicrobial use in NICUs should be implemented.